烧伤患者预防性使用益生菌:风险与获益
该回顾性队列研究纳入108例18至89岁烧伤患者,评估预防性口服益生菌对肠道功能、肠道微生物多样性和营养标志物的影响。结果显示益生菌组在治疗第1、2周腹泻报告更多,第2周C反应蛋白升高、前白蛋白降低,提示潜在吸收不良,且C. difficile感染、脓毒症、呕吐或胃残余量无差异,肠道微生物多样性未见获益。
要点
- 烧伤患者预防性使用益生菌未改善临床结局,反而与腹泻和吸收不良相关。
- 益生菌组第2周C反应蛋白升高、前白蛋白降低,提示潜在吸收不良。
- 益生菌未增加肠道微生物多样性,C. difficile感染和脓毒症率无差异。
核心结论
- 烧伤患者预防性使用益生菌与患者结局改善无关,反而可能与腹泻和吸收不良发生率增加相关。
- 在烧伤患者中常规使用益生菌前需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入108例18至89岁烧伤患者。
- 对8例患者通过16S定量PCR在标准益生菌方案前及全程追踪肠道微生物多样性。
主要发现
- 接受口服益生菌的患者在治疗第1周和第2周报告更多腹泻。
- 第2周益生菌组C反应蛋白水平升高,血清前白蛋白水平降低,提示潜在吸收不良。
- C. difficile感染、脓毒症率、呕吐或胃残余量无差异。
- 益生菌治疗未赋予肠道微生物多样性可识别的获益。
关键数值与推荐
- C. difficile检测用作腹泻存在的替代标志物。
- 测量血清C反应蛋白和前白蛋白值。
临床怎么用
- 烧伤患者不应常规预防性使用益生菌,需权衡腹泻和吸收不良风险。
- 对接受益生菌的烧伤患者应监测腹泻和营养标志物。
局限性
- 回顾性队列设计。
- 仅8例患者进行肠道微生物多样性追踪。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Probiotics are often used in critically ill patients to prevent antibiotic-associated complications, including Clostridium difficile colitis. However, clinical evidence of their efficacy is lacking. The objective of this study is to assess the impact of prophylactic probiotic administration on bowel function, gut microbial diversity, and nutritional markers in adult burn patients. A retrospective cohort study was done on 108 burn patients aged 18 to 89. Patients were given >1 million colony-forming units per day of Lactobacillus acidophilus and Lactobacillus rhamnosus. Testing for C. difficile was used as a surrogate marker for the presence of diarrhea. Serum C-reactive protein and prealbumin values were measured. Additionally, the gut microbial diversity of eight patients was tracked via 16S quantitative PCR before and throughout the course of a standard probiotic regimen. Patients receiving oral probiotics had more reported diarrhea in the first and second weeks of treatment. In the second week, C-reactive protein levels were increased, while serum prealbumin levels were lower in patients receiving probiotics, suggesting potential malabsorption. Additionally, there was no difference in C. difficile infection, sepsis rates, emesis, or gastric residuals, indicating an absence of therapeutic benefit for probiotic administration in burn patients. Furthermore, it was determined that no discernible benefit to gut microbial diversity was conferred by probiotic therapy. Prophylactic probiotics in burn patients are not associated with improvements in patient outcomes and may in fact be associated with an increased incidence of diarrhea and malabsorption. Additional research is needed before routine use in burn patients.
引用
- Fleming D, Jiang Y, Opoku K, et al. Prophylactic Probiotics in Burn Patients: Risk versus Reward. J Burn Care Res. 2019. PMID: 31326982. doi:10.1093/jbcr/irz132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。